2019 novel coronavirus (2019-nCoV) outbreak: A new challenge

Lupia, Tommaso; Scabini, Silvia; Pinna, Simone Mornese; Perri, Giovanni Di; Rosa, Francesco Giuseppe De; Corcione, Silvia

doi:10.1016/j.jgar.2020.02.021

Cited by 311 publications

(318 citation statements)

References 19 publications

Supporting

Mentioning

296

Contrasting

Unclassified

Order By: Relevance

“…1 Additional epidemiologic studies support this fi nding with low rates of pre-existing respiratory disease in patients with COVID-19. 2,3 Prior novel coronaviruses, SARS-CoV and MERS-CoV, did not appear to increase the risk of asthma exacerbations unlike seasonal coronaviruses, which have been linked to an increased risk. 4,5 There has been concern about the use of oral corticosteroids to treat an asthma exacerbation during the pandemic.…”

mentioning

confidence: 82%

Asthma increases risk of severity of COVID-19

Pennington

2020

CCJM

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 82%

Asthma increases risk of severity of COVID-19

Pennington

2020

CCJM

View full text Add to dashboard Cite

show abstract

“…The clinical spectrum of COVID-19 varies from asymptomatic or paucisymptomatic forms to clinical conditions characterized by severe respiratory failure that necessitates mechanical ventilation and support in an intensive care unit (ICU), to multiorgan and systemic manifestations in terms of sepsis, septic shock, and multiple organ dysfunction syndromes (MODS) [21]. Asymptomatic infections have also been described, but their frequency is unknown.…”

Section: Pathophysiology and Clinical Manifestationmentioning

confidence: 99%

Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review

Gennaro

Pizzol²,

Marotta

et al. 2020

IJERPH

647

480

View full text Add to dashboard Cite

At the end of 2019 a novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing severe acute respiratory syndrome expanded globally from Wuhan, China. In March 2020 the World Health Organization declared the SARS-Cov-2 virus a global pandemic. We performed a narrative review to describe existing literature with regard to Corona Virus Disease 2019 (COVID-19) epidemiology, pathophysiology, diagnosis, management and future perspective. MEDLINE, EMBASE and Scopus databases were searched for relevant articles. Although only when the pandemic ends it will be possible to assess the full health, social and economic impact of this global disaster, this review represents a picture of the current state of the art. In particular, we focus on public health impact, pathophysiology and clinical manifestations, diagnosis, case management, emergency response and preparedness. a natural and zoonotic origin: two scenarios that can plausibly explain the origin of SARS-CoV2 are: (i) natural selection in an animal host before zoonotic transfer; and (ii) natural selection in humans following zoonotic transfer [5,6]. Clinical features and risk factors are highly variable, making the clinical severity range from asymptomatic to fatal [7]. Understanding of COVID-19 is on-going. This review aims to summarize early findings on the epidemiology, clinical features, diagnosis, management, and prevention of COVID-19.

show abstract

“…Our search retrieved 1,063 publications, of which 175 were duplicates. Most publications were discarded after title and abstract analysis (n = 860), 28 were selected for full text screening and 18 were included in the final analysis ( Figure 1) [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31].…”

Section: Resultsmentioning

confidence: 99%

Coronavirus Disease (COVID-19) Pandemic: An Overview of Systematic Reviews

Nascimento

O’Mathúna

Groote

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Navigating the rapidly growing body of scientific literature on the SARS-CoV-2 pandemic is challenging and ongoing critical appraisal of this output is essential.We aimed to collate and summarize all published systematic reviews on the coronavirus disease .Methods: Nine databases (Medline, EMBASE, Cochrane Library, CINAHL, Web of Sciences, PDQ-Evidence, WHO's Global Research, LILACS and Epistemonikos) were searched from December 1, 2019 to March 24, 2020. Systematic reviews analyzing primary studies of COVID-19 were included. Two authors independently undertook screening, selection, extraction (data on clinical symptoms, prevalence, pharmacological and non-pharmacological interventions, diagnostic test assessment, laboratory and radiological findings) and quality assessment (AMSTAR 2). Meta-analysis on prevalence of clinical outcomes was performed.Results: Eighteen systematic reviews were included; one was empty. Using AMSTAR 2, confidence in the results of 13 reviews was rated as "critically low", one as "low", one as "moderate" and two as "high". Symptoms of COVID-19 were (range values of point estimates): fever (82-95%), cough with or without sputum (58-72%), dyspnea (26-59%), myalgia or muscle fatigue (29-51%), sore throat (10-13%), headache (8-12%) and gastrointestinal complaints (5-9%). Severe symptoms were more common in men. Elevated C-reactive protein (associated with lymphocytopenia) and lactate dehydrogenase, and slightly elevated aspartate and alanine aminotransferase, were commonly described. Thrombocytopenia and elevated levels of procalcitonin and cardiac troponin I were associated with severe disease. Chest imaging described a frequent pattern of uni-or bilateral multilobar ground-glass opacity. Only one review investigated the impact of medication (chloroquine) but found no verifiable clinical data. All-cause mortality ranged from 0.3% to 14%. Conclusions:Confidence in the results of most reviews was "critically low". Future studies and systematic reviews should adhere to established methodologies. The majority of included systematic reviews were hampered by imprecise search strategy and no previous protocol submission.All-cause mortality was 0.3% (95% CI 0.0%-1.0%). Epidemiological studies showed that mortality was higher in males and elderly patients. Clinical SymptomsThe incidence of symptoms were shown as following: Fever 82%, (CI) 56%-99%; Cough 61%, 95% CI 39%-81%; Muscle aches and/or fatigue 36%, 95% CI 18%-55%; Dyspnea 26%, 95% CI 12%-41%; Headache 12%, 95% CI 4%-23%; Sore throat 10%, 95% CI 5%-17% and gastrointestinal symptoms 9%,95% CI 3%-17%.

show abstract

2019 novel coronavirus (2019-nCoV) outbreak: A new challenge

Cited by 311 publications

References 19 publications

Asthma increases risk of severity of COVID-19

Asthma increases risk of severity of COVID-19

Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review

Coronavirus Disease (COVID-19) Pandemic: An Overview of Systematic Reviews

Contact Info

Product

Resources

About